Document is current
Any future updates will be listed below
-
Authors
He, Chujun
Amodio, Matthew
Ashenberg, Orr
Wucherpfennig, Kai W. https://orcid.org/0000-0002-1829-302X
Xavier, Ramnik J.
Uhler, Caroline https://orcid.org/0000-0002-7008-0216
- License Information
-
More Information
Article History
Received: 20 June 2025
Accepted: 26 February 2026
First Online: 12 March 2026
Competing interests
: KWW serves on the scientific advisory boards of DEM BioPharma, Solu Therapeutics, D2M Biotherapeutics, DoriNano, Inc., and Nextechinvest. He is a co-founder of Immunitas Therapeutics and receives sponsored research funding from Fate Therapeutics. He holds equity in TScan Therapeutics. RJX is Board Director at MoonLake Immunotherapeutics, and Scientific Advisory Board member at Nestle, Magnet Biomedicine, and Arena Bioworks, Co-founder of Convergence Bio; these organizations had no role in this study. CU serves on the Scientific Advisory Board of Immunai and Relation Therapeutics and has received sponsored research support from AstraZeneca and Janssen Pharmaceuticals. These activities are not related to the research reported in this study. The remaining authors declare no competing interests.
